EGFR targeted monoclonal antibodies (mAbs), such as cetuximab and panitumumab, are a valid therapeutic strategy for metastatic colorectal (CRC) patients. However, only in a subset of patients with metastatic CRC the addition of these mAbs to chemotherapy increases response rate, progression free survival and overall survival. Patients who initially respond to anti-EGFR therapies will relapse in few months due to development of secondary resistance that limits its clinical efficacy. Further understanding of the molecular alterations of relapse to EGFR blockade is extremely relevant to develop novel therapeutic strategies. In this study, we have demonstrated that in xenograft models, using three human CRC cell lines that are highly dependent on the EGFR pathway, the use of maintenance combined treatment with cetuximab plus MEK 1/2 inhibitor after an induction therapy of irinotecan plus cetuximab, is effective in preventing and/ or overcoming acquired resistance to anti-EGFR inhibitor and in prolonging mice survival. 
In the absence of alteration in RAS or its immediate downstream effectors, other mechanisms have been involved in the activation of the EGFR pathway. Genetic aberrations in receptor tyrosine kinase such as HER2 and MET have been shown to bypass EGFR signaling and activate the MAPK cascade and, therefore to confer acquired resistance to anti-EGFR therapies (19-22).
As with HER2 and MET, alterations to EGFR can contribute to acquired resistance to anti-EGFR (23-25). In a model of colon cancer cell line with acquired resistance to cetuximab, sequencing analysis of the EGFR gene revealed a missense mutation (S492R), which was shown to responsible of cetuximab resistance (23).
It has been demonstrated that another mechanism of acquired resistance to EGFR inhibitors could be an increased secretion of VEGF, suggesting a key role for tumor-induced angiogenesis in the development of anti-EGFR resistance (26-27).
The plethora of alterations that are responsible of both primary and acquired resistant mechanisms to anti-EGFR inhibitors in the treatment of metastatic CRC, biochemically converge in to two "critical points": MEK-ERK and PIK3CA-AKT pathways. Based on this evidence, we hypothesized that inhibiting simultaneously these survival pathways could render more difficult for cancer cells to escape EGFR blockade. Moreover, if these survival routes are blocked without allowing the tumor to escape from the initial treatment, the time required to develop resistance could be delayed.
We performed an in vivo study using human CRC cell lines highly sensitive to EGFR inhibitors, in order to evaluate which maintenance treatment with different inhibitors downstream of the EGFR pathway, could be able to prevent and/or delay the onset of resistance after an induction treatment with cetuximab plus irinotecan. Among different maintenance treatments we selected three inhibitors, such as regorafenib, GDC-0941 (a selective PIK3CA inhibitor), BAY86-9766 (a selective MEK 1/2 inhibitor) alone or in combination with cetuximab. week for three weeks. Subsequently, groups of 70 mice each were injected subcutaneously with SW48, GEO or LIM 1215 human colon cancer cell lines. After two weeks, animals were treated with irinotecan (100mg/kg once a week, i.p.) plus cetuximab (1mg twice a week, i.p.). At the end of three weeks of therapy, defined as induction treatment mice were randomized into 8 groups (n=10 mice per group) as shown in Figure 2 . Cetuximab (1 mg twice a week, i.p.) was dosed i.p., whereas BAY 86-9766 (25mg/kg every day for 5 days a week), GDC-0941 (75mg/kg every day for 5 days a week) and regorafenib (10mg/kg every day for 5 days a week) were given by oral gavage. The maintenance treatment was continued for 8 weeks and afterwards animals were followed for additional 17 weeks (follow-up period). The mice body weights were monitored and tumors were measured with a caliper using the following formula: π/6 x larger diameter x (smaller diameter) 2 . At the end of maintenance treatment, five animals per group were sacrificed and four tumor samples were collected for multiple gene mutation analysis by next-generation sequencing, whereas one was used for Western Blot analysis.
Immunoblotting. Tumor sample were harvested form euthanized mice, cut into 20-25 mm 3 pieces and frozen at -80 C in RNA later. Subsequently frozen samples were homogenised in RIPA lyses buffer (0,1% sodium dodecylsulphate (SDS), 0,5% deoxycholate, 1% Nonidet, 100mM NaCl, 10 mM Tris-HCl (pH 7,4)) containing a protease inhibitor cocktail (Hoffmann-La Roche, Basel, 
Results
The combination of irinotecan and cetuximab lead to enhanced antitumor efficacy in CRC xenograft models.
In the present study, we have selected three human colorectal cancer cell lines (SW48, GEO and LIM1215) that are sensitive to EGFR inhibition (33) (34) (35) . In particular the SW48 and LIM 1215 cell lines function as a relevant model for metastatic CRC patients that would receive cetuximab treatment as neither of cell line has genetic alterations that are known to be associated with intrinsic resistance to anti-EGFR therapies (KRAS, BRAF, and PIK3CA) (7; [34] [35] [36] . On the contrary, GEO cells display a different genetic profile, harboring KRAS codon 12 mutation (34) . Despite KRAS gene mutation, previous studies from different laboratories, including our own, demonstrated that this CRC cell line is one of the most sensitive to the in vitro and in vivo antitumor activity of cetuximab treatment (34) (35) (36) .
Mice were treated intraperitoneally for three weeks with cetuximab, irinotecan and their combination. As shown in Figure 1 , both agents determined in all three models a tumor growth inhibition that was more pronounced in the cetuximab arm reaching a statistical difference compared with control (p< 0.05). In addition, the combination of irinotecan plus cetuximab resulted in tumor regression during the treatment period ( Figure 1 ). The combined treatment was well tolerated with no weight loss or other signs of acute or delayed toxicity (data not shown).
Trial design and treatment plan.
The mechanisms of acquired resistance to EGFR blockade that have been confirmed clinically range from genetic alterations in members of the EGFR-RAS-RAF-MEK pathway to activation of pathways driven by other receptor tyrosine kinases (RTKs), such as MET, ERBB2 or VEGFR1 (17-26). A possible strategy to overcome acquired resistance is to prevent it from emerging by using combination treatment as first line targeted therapy rather than after the patient has progressed on therapy. Based on this assumption, we designed an in vivo study in which each of three CRC cell lines described above was injected subcutaneously into right flank of a group of 80 female nude mice. After two weeks from the injection, mice were treated for three weeks with the combination of irinotecan (100 mg/kg once a week) plus cetuximab (1 mg twice a week). These doses were chosen, on the basis of the previous experiment, as the optimal doses that were able to determine tumor growth inhibition after three weeks of treatment without relevant side effects (Figure 1 ). At the ends of this induction treatment, mice were randomized into 8 group (10 per group) and treated for eight weeks with several kinase inhibitors, such as regorafenib , GDC-0941 (a selective PIK3CA inhibitor), BAY86-9766 (a selective MEK 1/2 inhibitor) alone or in combination with cetuximab ( Figure 2A ). After this maintenance treatment mice were followed for another 17 weeks.
Antitumor efficacy of irinotecan plus cetuximab followed by maintenance treatment in human CRC xenograft models. 
Discussion
The understanding of molecular features of tumors has revealed that cancer genomes are highly heterogeneous especially in the case of metastatic dissemination (39). These characteristics may explain why treatments with individual drugs, such as anti-EGFR inhibitors, have limited effectiveness. In particular, the clinical limitation of the two monoclonal antibodies, cetuximab and panitumumab, in the treatment of metastatic CRC due to emergence of secondary resistance prompted us to study how this problem could be potentially tackled. The idea of this in vivo study has been founded on two considerations: first that mechanisms of acquired resistance to anti-EGFR inhibitors in the treatment of metastatic CRC are extremely heterogeneous ranging from genetic mutations of the EGFR-RAS-RAF-MEK to activation of independent pathways driven by other tyrosine kinases receptors (RTKs) (40-41). This suggests that the concomitant blockade of signaling nodes that could confer resistance to anti-EGFR inhibitors might be a possible strategy to overcome it. Second, that if these signaling pathways are blocked from the beginning without offering the tumor the possibility to first escape the initial treatment, the time required to develop resistance could be extended. As a proof of concept, we used three CRC cell lines that are highly sensitive to EGFR inhibitions, grown as tumor xenograft in nude mice. We treated mice for three weeks with a combination of irinotecan plus cetuximab that is considered a possible strategy to treat metastatic CRC patients harboring no mutations in RAS genes as first line therapy (10) . Before tumor started to regrowth and eventually possible resistance mechanisms to targeted agents will occur, mice were randomized to maintenance treatments with several inhibitors, such as regorafenib, PI3Ki, MEKi alone or in combination with cetuximab.
The results of this study suggest that the combined treatment with cetuximab plus MEKi, after an induction therapy of irinotecan and cetuximab, is able to prevent and/ or overcome the resistance to anti-EGFR inhibitors. In particular, maintenance treatment for eight weeks with cetuximab plus 
MEKi after a three weeks induction treatment with irinotecan plus cetuximab is highly effective in increasing tumor growth inhibition with 60 to 80% major tumor responses in the three CRC cell models that were studied and with 2 out of 10 mice cured in the combination cetuximab plus MEKi.
This antitumor activity was translated in a better antitumor efficacy since median overall survival was significantly increased from 10 to 12 weeks in mice treated with cetuximab alone to approximately 30 weeks in mice treated with cetuximab plus MEKi.
In agreement with these results, some preclinical and clinical studies have shown that combination therapy is able to delay the onset of resistance to BRAF inhibitors in the treatment of One of the most common molecular mechanism that drive secondary resistance to anti-EGFR therapy in metastatic CRC patients is the acquisition of new genetic alteration of KRAS, NRAS and BRAF genes (13, (16) (17) (18) . In particular, under the pressure of a selective treatment, resistant subclones preexisting in the initial tumor cell population will be selected and will be responsible of the resistance. These cancer cell populations cannot be detected by gene sequencing but could be found with more sensitive approaches such as NGS. In particular in our experiment, mutation profiling revealed molecular alterations only in KRAS and BRAF following treatment with different inhibitors. Furthermore, the highest frequency of mutations in KRAS gene was found in the group treated with MEKi alone, whereas it decrease in the cetuximab plus MEKi combined treatment group. These results suggest that the combination treatment with cetuximab and MEKi prevents or delays the selection of clones that carry the mutation in genes responsible of acquired resistance to anti-EGFR inhibitors. There is some evidence, though, that mutations that lead to resistance can be acquired during drug treatment. In fact, similar to our results, Misale et al. were unable to detect the LIM1215 cetuximab resistant KRAS G12R mutation in the LIM1215 parental cells implying that this mutation was acquired during treatment (15). Moreover the EGFR S492 gene mutation that was demonstrated responsible for the acquisition of cetuximab resistance was not found in metastatic CRC patients before anti-EGFR treatment (33, 44) .
Another important finding in the present study is the detection of the activation of alternative survival pathways, such as the activation of MET and IGFR-1 signaling under the pressure of selective drugs, as a mechanism of acquired resistance to anti-EGFR inhibitors. In particular, we found that biochemical activation of these pathways could be detected before of clinical progression was documented by the increase in tumor size in mice. In conclusion, the acquired resistance to anti-EGFR inhibitors can be defined as a consequence of a perturbation in a system in which the initial equilibrium is based on cell that are addicted to EGFR signaling. The evidence that most of the mutations that emerge upon treatment involve genes that are direct members of the EGFR pathways indicate that to escape the perturbations, the cells must settle on a new balance which is based again on EGFR signaling. This is supported by this study 
